What do systematic reviews say?

Rituximab/cyclosporin/prednisolone vs cyclosporin/prednisolone

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Very low

Rituximab/cyclosporin/prednisolone vs cyclosporin/prednisolone

It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in delayed… compared with cyclosporin/prednisolone (very low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.14 [0.33, 3.94]
  1 study · 15 participants
  Very low

Rituximab/cyclosporin/prednisolone vs cyclosporin/prednisolone

It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in all patients compared with cyclosporin/prednisolone (very low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.94 [0.22, 3.94]
  1 study · 31 participants
  Very low

Rituximab/cyclosporin/prednisolone vs cyclosporin/prednisolone

It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: bronchospasm/treatment discontinued compared with cyclosporin/prednisolone (very low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 2.82 [0.12, 64.39]
  1 study · 31 participants
  Very low

Rituximab/cyclosporin/prednisolone vs cyclosporin/prednisolone

It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 2.82 [0.12, 64.39]
  1 study · 31 participants
  Very low

Rituximab/cyclosporin/prednisolone vs cyclosporin/prednisolone

It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: skin rash compared with cyclosporin/prednisolone (very low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 6.59 [0.37, 117.77]
  1 study · 31 participants
  Very low

Rituximab/cyclosporin/prednisolone vs cyclosporin/prednisolone

It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: mild dyspnoea compared with cyclosporin/prednisolone (very low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 4.71 [0.24, 90.69]
  1 study · 31 participants
  Very low